Key Drivers
- High gross margins
- Interest coverage shortfall
- Large intangible risk
AIAI Summary
HROW has shifted into a capital‑light, cash‑generating commercial profile—driven by rising OCF, high gross margins and targeted sales investments in VEVYE/IHEEZO—but its large $251M debt, interest expense exceeding EBIT and concentrated receivables mean a single revenue or collections miss could quickly force external financing or impairments.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margins
- •Interest coverage shortfall
- •Large intangible risk
HROW shows strong unit economics and improving quarterly profitability with solid cash flow, but extremely high leverage, insufficient FY interest coverage, heavy intangibles and a very rich market valuation pose significant downside risk.
Price Behavior
Key Price Behavior Insights:
- •Persistent downtrend
- •Deeply oversold
- •Clear nearby support
Stock is in a clear downtrend with price well below the last-month SMA after a sharp one-day sell-off on 2026-03-03, trading near $33–$34 support while deeply oversold (RSI<30) signaling a possible short-term bounce but facing layered resistance in the mid/high 30s and low 50s.
Sharp one-day sell-off on 2026-03-03 causing elevated volatility and a lower trading range
Sentiment & News
Key News Insights:
- •Revenue acceleration
- •Earnings miss
- •Clinical momentum
Harrow delivered strong revenue growth (36% FY) and record Q4 sales but missed EPS and issued cautious guidance, prompting a ~30–35% stock pullback amid margin and leverage concerns despite positive cash flow and clinical progress.
Expect continued volatility and valuation pressure until margin improvement or near-term clinical/commercial milestones materially reduce execution and leverage risks
Similar Companies in Healthcare
Other companies in the same sector with AI ratings